Skip to main content

Adjuvant hormonal therapy is recommended or administered within 1 year (365 days) of diagnosis for women with AJCC T1cN0M0 or Stage IB – Stage III hormone receptor positive breast cancer

CBE ID
0220
Project
Cancer
Endorsed
New or Maintenance
Maintenance
Endorsement and Maintenance (E&M) Cycle
Fall 2019
Is Under Review
No
Measure Description

Percentage of female patients, age = 18 at diagnosis, who have their first diagnosis of cancer (epithelial malignancy), at AJCC T1cN0M0 or stage IB to IIIC, whose primary tumor is of the breast, and is progesterone or estrogen receptor positive with adjuvant hormonal therapy (recommended or administered) within 1 year (365 days) of diagnosis

  • Measure Type
    Process
    Electronic Clinical Quality Measure (eCQM)
    No
    Level Of Analysis
    Facility
    Care Setting
    Inpatient/Hospital
    Numerator

    Adjuvant hormonal therapy is administered within 1 year (365 days) of the date of diagnosis or it is recommended but not administered

    Denominator

    Include if all of the following characteristics are identified:
    Women
    Age = 18 at time of diagnosis
    Known or assumed to be first or only cancer diagnosis
    Epithelial malignancy only
    Invasive tumors
    Primary tumors of the breast
    AJCC T1cN0M0 or Stage IB – IIIC
    Primary tumor is estrogen receptor positive or progesterone receptor positive
    All or part of 1st course of treatment performed at the reporting facility
    Known to be alive within 1 year (365 days) of date of diagnosis
    Surgical procedure of the primary site

    Exclusions

    Exclude, if any of the following characteristics are identified:
    Men
    Under age 18 at time of diagnosis
    Second or subsequent cancer diagnosis
    Tumor not originating in the breast
    Non-epithelial malignancies, exclude malignant phyllodes tumors; 8940 - Mixed tumor, malignant, NOS; 8950 - Mullerian mixed tumor; 8980 - Carcinosarcoma; 8981 - Carcinosarcoma, embryonal
    Non-invasive tumors
    Stage 0, in-situ tumor
    Stage IV, metastatic tumor
    Primary tumor is estrogen receptor negative and progesterone receptor negative
    None of 1st course therapy performed at reporting facility
    Died within 1 year (365 days) of diagnosis,
    Patient enrolled in a clinical trial that directly impacts delivery of the standard of care
    No surgical procedure of the primary site
    Not AJCC T1cN0M0 or not AJCC stage IB-IIIC

    Testing Data Sources
    Registry data
  • Most Recent Endorsement Activity
    Endorsed Cancer Fall Cycle 2019
    Initial Endorsement
    Next Planned Maintenance Review
    Cancer Fall 2023
    Endorsement Status
    Endorsed
    Last Updated